Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/21/2020 10/22/2020 10/23/2020 10/26/2020 10/27/2020 Date
7920(c) 7955(c) 7943(c) 8077(c) 8056 Last
1 410 226 1 467 484 999 438 1 245 512 1 514 561 Volume
-1.81% +0.44% -0.15% +1.69% -0.26% Change
More quotes
Financials (USD)
Sales 2020 26 684 M - -
Net income 2020 3 050 M - -
Net Debt 2020 13 182 M - -
P/E ratio 2020 48,7x
Yield 2020 2,68%
Sales 2021 30 229 M - -
Net income 2021 4 423 M - -
Net Debt 2021 11 281 M - -
P/E ratio 2021 33,8x
Yield 2021 2,71%
Capitalization 138 B 138 B -
EV / Sales 2020 5,66x
EV / Sales 2021 4,94x
Nbr of Employees 70 600
Free-Float 95,7%
More Financials
Company
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - oncology (36.8%); - respiratory diseases (22.9%); - cardiovascular, renal and metabolic diseases (18.6%); - other (21.7%): inflammatory and autoimmune diseases, neurological diseases, gastrointestinal and infectious diseases. Net sales are distributed geographically as follows: the United... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
More about the company
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
More Ratings
All news about ASTRAZENECA PLC
12:36pEU warns not enough COVID vaccines for all in Europe until 2022
RE
12:36pUK starts real-time review of Moderna's COVID-19 vaccine candidate
RE
11:53aPfizer Says Covid-19 Vaccine Late-Stage Trial Almost Fully Enrolled -- 2nd Up..
DJ
11:24aMerck says early data from COVID-19 vaccines expected this year
RE
10:12aNovavax delays U.S. trial of COVID-19 vaccine candidate to November
RE
09:58aMODERNA : UK starts real-time review of Moderna's COVID-19 vaccine candidate
RE
08:14aPandemic Dents Third-Quarter Sales for Pfizer -- Update
DJ
06:57aASTRAZENECA : WRAPUP 6-Europe enacts new curbs as COVID surges in absence of vac..
RE
05:34aEuropean shares sink to one-month lows as COVID-19 cases surge
RE
04:25aS.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26Health Care Shares Decline as Covid-19 Continues to Dominate Headlines -- Hea..
DJ
10/26NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/26Travel, energy stocks drag UK shares lower, weighed by coronavirus fears
RE
More news
News in other languages on ASTRAZENECA PLC
01:22aCORONAVIRUS : le point sur la pandémie
10/26A Wall Street, le Dow Jones connaît sa pire séance depuis septembre
10/26LONDON STOCK EXCHANGE : Londres déstabilisée par la flambée des contaminations
10/26ASTRAZENECA : soutenu par des nouvelles encourageantes concernant son vaccin
10/26DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 26.10.2020 - 15.15 Uhr
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,34 $
Last Close Price 105,12 $
Spread / Highest target 47,9%
Spread / Average Target 12,6%
Spread / Lowest Target -37,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC6.18%137 968
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381